Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1;37(7):1584-1600.e10.
doi: 10.1016/j.cmet.2025.04.001. Epub 2025 Apr 22.

Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction

Affiliations

Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction

Yuki Tatekoshi et al. Cell Metab. .

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a common cause of morbidity and mortality worldwide, but its pathophysiology remains unclear. Here, we report a mouse model of HFpEF and show that hexokinase (HK)-1 mitochondrial binding in endothelial cells (ECs) is critical for protein O-GlcNAcylation and the development of HFpEF. We demonstrate increased mitochondrial dislocation of HK1 within ECs in HFpEF mice. Mice with deletion of the mitochondrial-binding domain of HK1 spontaneously develop HFpEF and display impaired angiogenesis. Spatial proximity of dislocated HK1 and O-linked N-acetylglucosamine transferase (OGT) causes increased OGT activity, shifting the balance of the hexosamine biosynthetic pathway intermediates into the O-GlcNAcylation machinery. EC-specific overexpression of O-GlcNAcase and an OGT inhibitor reverse angiogenic defects and the HFpEF phenotype, highlighting the importance of protein O-GlcNAcylation in the development of HFpEF. Our study demonstrates a new mechanism for HFpEF through HK1 cellular localization and resultant protein O-GlcNAcylation, and provides a potential therapy for HFpEF.

Keywords: HFpEF; O-GlcNAcylation; endothelial cell; hexokinase 1; mitochondria.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests H.A. and Y.T. are listed as inventors on a patent application (18/412,362) filed on January 12, 2024, related to the subject matter of this research.

Update of

References

    1. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, and Liu PP (2006). Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355, 260–269. 10.1056/NEJMoa051530. - DOI - PubMed
    1. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB, et al. (2007). Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50, 768–777. 10.1016/j.jacc.2007.04.064. - DOI - PubMed
    1. Kardys I, Deckers JW, Stricker BH, Vletter WB, Hofman A, and Witteman JC (2009). Echocardiographic parameters and all-cause mortality: the Rotterdam Study. Int J Cardiol 133, 198–204. 10.1016/j.ijcard.2007.12.031. - DOI - PubMed
    1. Xu B, and Daimon M (2016). Cardiac aging phenomenon and its clinical features by echocardiography. J Echocardiogr 14, 139–145. 10.1007/s12574-016-0292-6. - DOI - PubMed
    1. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, and Carson PE (2011). Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 4, 324–331. 10.1161/CIRCHEARTFAILURE.110.959890. - DOI - PMC - PubMed

Substances

LinkOut - more resources